Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Patrys Limited (DE:A1N)
BERLIN:A1N
Holding DE:A1N?
Track your performance easily
A1N Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€0.01
Volume190.00K
Average Volume (3M)N/A
Market Cap
€3.79M
Enterprise Value-€2.16M
Total Cash (Recent Filing)AU$9.82M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Feb 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.33
R-Squared0.00817
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1924.98
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Patrys Limited News
PremiumCompany Announcements
Patrys Limited Shifts Focus to Promising Antibody PAT-DX3
PremiumCompany Announcements
Patrys Limited Announces Virtual AGM for 2024
PremiumCompany Announcements
Patrys Limited Refocuses on Promising PAT-DX3 AntibodyPremiumCompany Announcements
Patrys Limited Reports Delay in Cancer Drug TestingPremiumCompany Announcements
Patrys Limited Upholds Corporate Governance Standards
PremiumCompany Announcements
Patrys Limited Cuts Annual Losses by HalfPremiumCompany Announcements
Patrys Limited Faces Delay in PAT-DX1 Drug Development
PremiumCompany Announcements
Patrys Limited Reports Progress and PotentialA1N FAQ
What was Patrys Limited’s price range in the past 12 months?
Currently, no data Available
What is Patrys Limited’s market cap?
Currently, no data Available
When is Patrys Limited’s upcoming earnings report date?
Patrys Limited’s upcoming earnings report date is Feb 21, 2025 which is in 103 days.
How were Patrys Limited’s earnings last quarter?
Patrys Limited released its earnings results on Aug 23, 2024. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Patrys Limited overvalued?
According to Wall Street analysts Patrys Limited’s price is currently Overvalued.
Does Patrys Limited pay dividends?
Patrys Limited does not currently pay dividends.
What is Patrys Limited’s EPS estimate?
Patrys Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Patrys Limited have?
Patrys Limited has 2,057,447,300 shares outstanding.
What happened to Patrys Limited’s price movement after its last earnings report?
Patrys Limited reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Patrys Limited?
Currently, no hedge funds are holding shares in DE:A1N
---
Patrys Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-68.67%
Trailing 12-Months
Asset Growth
-44.69%
Trailing 12-Months
Company Description
Patrys Limited
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 and PAT-DX1-NP, and PAT-LM1. Its lead technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody which penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.
---
Qube Holdings Ltd.
―
Noxopharm Ltd.
―
Vectus Biosystems Limited
―
Chimeric Therapeutics Ltd.
―
---